Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs

作者:Lillethorup Thea P; Glud Andreas N; Alstrup Aage K O; Mikkelsen Trine W; Nielsen Erik H; Zaer Hamed; Doudet Doris J; Brooks David J; Sorensen Jens Christian H; Orlowski Dariusz; Landau Anne M*
来源:Experimental Neurology, 2018, 303: 142-152.
DOI:10.1016/j.expneurol.2018.02.005

摘要

Parkinson's disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra leading to slowness and stiffness of limb movement with rest tremor. Using ubiquitin proteasome system inhibitors, rodent models have shown nigrostriatal degeneration and motor impairment. We translated this model to the Gottingen minipig by administering lactacystin into the medial forebrain bundle (MFB). Minipigs underwent positron emission tomography (PET) imaging with (+)-alpha-[C-11]dihydrotetrabenazine ([C-11]DTBZ), a marker of vesicular monoamine transporter 2 availability, at baseline and three weeks after the unilateral administration of 100 mu g lactacystin into the MFB. Compared to their baseline values, minipigs injected with lactacystin showed on average a 36% decrease in ipsilateral striatal binding potential corresponding to impaired presynaptic dopamine terminals. Behaviourally, minipigs displayed asymmetrical motor disability with spontaneous rotations in one of the animals. Immunoreactivity for tyrosine hydroxylase (TH) and HLA-DR-positive microglia confirmed asymmetrical reduction in nigral TH-positive neurons with an inflammatory response in the lactacystin-injected minipigs. In conclusion, direct injection of lactacystin into the MFB of minipigs provides a model of PD with reduced dopamine neurotransmission, TH-positive neuron reduction, microglial activation and behavioural deficits. This large animal model could be useful in studies of symptomatic and neuroprotective therapies with translatability to human PD.

  • 出版日期2018-5